244 related articles for article (PubMed ID: 10864222)
1. Systemic therapy emergencies.
Albanell J; Baselga J
Semin Oncol; 2000 Jun; 27(3):347-61. PubMed ID: 10864222
[TBL] [Abstract][Full Text] [Related]
2. Extravasation of chemotherapeutic agents: prevention and treatment.
Goolsby TV; Lombardo FA
Semin Oncol; 2006 Feb; 33(1):139-43. PubMed ID: 16473651
[TBL] [Abstract][Full Text] [Related]
3. [The significance of extravasation in oncological care].
Zatkóné Puskás G
Magy Onkol; 2008 Mar; 52(1):75-80. PubMed ID: 18403301
[TBL] [Abstract][Full Text] [Related]
4. [Extravasation of chemotherapeutic agents: prevention and therapy].
Jordan K; Grothe W; Schmoll HJ
Dtsch Med Wochenschr; 2005 Jan; 130(1-2):33-7. PubMed ID: 15619172
[TBL] [Abstract][Full Text] [Related]
5. Antidotes to vesicant chemotherapy extravasations.
Dorr RT
Blood Rev; 1990 Mar; 4(1):41-60. PubMed ID: 2182147
[TBL] [Abstract][Full Text] [Related]
6. European Oncology Nursing Society extravasation guidelines.
Wengström Y; Margulies A;
Eur J Oncol Nurs; 2008 Sep; 12(4):357-61. PubMed ID: 18765210
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of perivascular extravasation of cytostatic agents].
Rauh J; Pluntke S; Müller Ch
MMW Fortschr Med; 2004 Aug; 146(31-32):23-4, 26-7. PubMed ID: 15529703
[TBL] [Abstract][Full Text] [Related]
8. Case report: topical DMSO for mitomycin-C-induced skin ulceration.
Alberts DS; Dorr RT
Oncol Nurs Forum; 1991; 18(4):693-5. PubMed ID: 1906166
[TBL] [Abstract][Full Text] [Related]
9. Extravasation of systemic hemato-oncological therapies.
Ener RA; Meglathery SB; Styler M
Ann Oncol; 2004 Jun; 15(6):858-62. PubMed ID: 15151940
[TBL] [Abstract][Full Text] [Related]
10. [Cytostatic drug extravasation--are there new recommendations for therapeutic management?].
Fenchel K; Karthaus M
Wien Med Wochenschr; 2001; 151(3-4):44-6. PubMed ID: 11789418
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Lee C; Gianos M; Klaustermeyer WB
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):179-87; quiz 187-9, 222. PubMed ID: 19354063
[TBL] [Abstract][Full Text] [Related]
12. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
13. [Neurotoxicity and dermatologic toxicity of cancer chemotherapy].
Nakane M
Gan To Kagaku Ryoho; 2006 Jan; 33(1):29-33. PubMed ID: 16410694
[TBL] [Abstract][Full Text] [Related]
14. Prevention and management of extravasation of cytotoxic drugs.
Bertelli G
Drug Saf; 1995 Apr; 12(4):245-55. PubMed ID: 7646823
[TBL] [Abstract][Full Text] [Related]
15. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration.
Bryant R
J Intraven Nurs; 2001; 24(3):169-73. PubMed ID: 11530362
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity reactions to antineoplastic agents: an overview.
Syrigou E; Makrilia N; Koti I; Saif MW; Syrigos KN
Anticancer Drugs; 2009 Jan; 20(1):1-6. PubMed ID: 19342995
[TBL] [Abstract][Full Text] [Related]
18. Managing vesicant extravasations.
Schulmeister L
Oncologist; 2008 Mar; 13(3):284-8. PubMed ID: 18378538
[TBL] [Abstract][Full Text] [Related]
19. Risk management of extravasation of cytostatic drugs at the Adult Chemotherapy Outpatient Clinic of a university hospital.
Adami NP; de Gutiérrez MG; da Fonseca SM; de Almeida EP
J Clin Nurs; 2005 Aug; 14(7):876-82. PubMed ID: 16000102
[TBL] [Abstract][Full Text] [Related]
20. Extravasation management.
Schulmeister L
Semin Oncol Nurs; 2007 Aug; 23(3):184-90. PubMed ID: 17693345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
